Baillie Gifford & Co. Invests $263.14 Million in Insulet Co. (NASDAQ:PODD)

Baillie Gifford & Co. purchased a new position in Insulet Co. (NASDAQ:PODD - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,212,759 shares of the medical instruments supplier's stock, valued at approximately $263,144,000. Baillie Gifford & Co. owned 1.74% of Insulet as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in PODD. Parkside Financial Bank & Trust increased its stake in shares of Insulet by 251.0% in the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 123 shares in the last quarter. Allworth Financial LP increased its stake in shares of Insulet by 104.5% during the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 92 shares in the last quarter. Wolff Wiese Magana LLC lifted its holdings in shares of Insulet by 2,680.0% during the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 134 shares during the last quarter. BluePath Capital Management LLC bought a new stake in shares of Insulet in the 3rd quarter worth approximately $31,000. Finally, First Manhattan Co. bought a new position in Insulet during the 4th quarter valued at approximately $35,000.

Insulet Stock Performance

Shares of Insulet stock traded down $0.60 during trading hours on Wednesday, reaching $177.41. 695,237 shares of the stock traded hands, compared to its average volume of 891,087. Insulet Co. has a one year low of $125.82 and a one year high of $335.91. The firm has a market capitalization of $12.41 billion, a price-to-earnings ratio of 60.97, a P/E/G ratio of 3.06 and a beta of 0.98. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86. The company has a 50 day moving average price of $177.41 and a 200 day moving average price of $178.42.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.73. The company had revenue of $509.80 million during the quarter, compared to analyst estimates of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The firm's quarterly revenue was up 37.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.55 earnings per share. On average, equities research analysts expect that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the firm's stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the sale, the director now owns 2,567 shares in the company, valued at approximately $418,215.64. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have commented on PODD. Piper Sandler dropped their target price on Insulet from $250.00 to $230.00 and set an "overweight" rating on the stock in a report on Friday, February 23rd. JPMorgan Chase & Co. increased their price objective on shares of Insulet from $190.00 to $225.00 and gave the company an "overweight" rating in a research report on Friday, February 23rd. Stifel Nicolaus raised their price objective on shares of Insulet from $163.00 to $208.00 and gave the company a "hold" rating in a research note on Monday, February 5th. Robert W. Baird upgraded shares of Insulet from a "neutral" rating to an "outperform" rating and upped their target price for the stock from $180.00 to $238.00 in a research note on Thursday, December 21st. Finally, Barclays reduced their price target on shares of Insulet from $214.00 to $213.00 and set an "equal weight" rating for the company in a research report on Monday, February 26th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $250.33.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.